Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

withdrawn133%

completed267%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma

NCT00036972

completedphase_1

Immunotoxin Therapy in Treating Patients With Malignant Glioma

NCT00006268

withdrawnphase_1

Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas

NCT00053040

Clinical Trials (3)

Showing 3 of 3 trials

NCT00036972Phase 1

Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma

Completed

NCT00006268Phase 1

Immunotoxin Therapy in Treating Patients With Malignant Glioma

Completed

NCT00053040Phase 1

Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3